MedTrace Logo

Acamprosate: Genes Associated With Response

NCT00662571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 485

Last updated 2013-03-22

No results posted yet for this study

Summary

In 2004, acamprosate was approved in the U.S. for abstinence maintenance, by decreasing craving, in alcoholic patients who have undergone detoxification. while a new anti-craving drug was encouraging, only 36.1% of the subjects treated with acamprosate remained abstinent for 6 months. Having the ability to identify treatment responsive individuals would have a major impact on the use of acamprosate.

Conditions

  • Alcoholism

Interventions

DRUG

acamprosate

acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day

Sponsors & Collaborators

  • Samuel C. Johnson Foundation

    collaborator UNKNOWN

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • David Mrazek, M.D. · Mayo Clinic, Department of Psychiatry

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00662571 on ClinicalTrials.gov